These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35264135)

  • 1. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
    BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Waterhouse D; Lam J; Betts KA; Yin L; Gao S; Yuan Y; Hartman J; Rao S; Lubinga S; Stenehjem D
    Lung Cancer; 2021 Jun; 156():41-49. PubMed ID: 33894493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
    Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
    BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.
    Bearz A; Passalacqua R; Alabiso O; Cinieri S; Gridelli C; Cravesana C; Crinò L
    Clin Drug Investig; 2012 Nov; 32(11):755-60. PubMed ID: 23018280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States.
    Haque W; Verma V; Butler EB; Teh BS
    Anticancer Res; 2019 Jun; 39(6):3137-3140. PubMed ID: 31177159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.
    Seung SJ; Hurry M; Walton RN; Evans WK
    Curr Oncol; 2020 Aug; 27(4):e361-e367. PubMed ID: 32905294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
    Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
    Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
    Kehl KL; Hassett MJ; Schrag D
    Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative.
    Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Daumont MJ; Penrod JR; Hall G
    BMJ Open; 2021 Sep; 11(9):e046396. PubMed ID: 34526333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
    Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
    Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
    Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
    Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
    Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage Non-Small Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy: A Population-based Analysis.
    Haque W; Szeja S; Tann A; Kalra S; Teh BS
    Am J Clin Oncol; 2018 Mar; 41(3):259-266. PubMed ID: 26771443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.